Department of Gastrointestinal Surgery, West China Hospital of Sichuan University, No. 37 Guoxue Lane, Chengdu, 610041, Sichuan, China.
West China School of Nursing, Sichuan University/Nursing Department, West China Hospital of Sichuan University, No. 37 Guoxue Lane, Chengdu, 610041, Sichuan, China.
Langenbecks Arch Surg. 2022 Dec;407(8):3275-3285. doi: 10.1007/s00423-022-02517-5. Epub 2022 Jun 6.
Self-expandable metallic stent (SEMS), an alternative to diverting stoma (DS), has been used as a "bridge to surgery" (BTS) to decompress acute obstruction of colorectal cancer (CRC) for decades. However, whether SEMS is a safe technique for obstruction of CRC without compromising the long-term survival of patients remains unidentified compared to those of DS. The aim of the present study was to elucidate the safety and survival outcomes of SEMS and DS.
Embase, PubMed, and Medline were searched for qualified studies published until October, 2020, in which SEMS or DS was performed as a BTS without resection at the same stage. The last search was on December 5th, 2020. The Newcastle-Ottawa scale (NOS) was used to assess the quality of included studies. The major complication rate, mortality, 3-year overall survival (OS), and permanent stoma rate were estimated as outcomes.
The present study was registered on INPLASY (No. 2020100079). Seven eligible studies were included, involving 646 and 712 patients who underwent SEMS and DS treatments, respectively. The Clavien-Dindo I/II grade complication rate was significantly lower in the SEMS group than in the DS group (8.68 vs. 16.85%; RR, 0.59; 95% confidence interval (CI) 0.41-0.84; P = 0.004). The Clavien-Dindo III/IV grade complication rate was comparable in two groups (7.69 vs. 8.79%; RR, 0.82; 95% CI 0.54-1.27; P = 0.37). There were no statistical differences in the short-term mortality (5.16 vs. 4.53%; RR, 1.25; 95% CI 0.75-2.08; P = 0.39), 3-year OS (71.91 vs. 76.60%; RR, 0.93; 95% CI 0.86-1.01; P = 0.10), and permanent stoma rate (22.08 vs. 27.54%; RR, 0.84; 95% CI 0.67-1.06; P = 0.14) between the two groups.
To some extent, SEMS is a safe BTS technique for acute obstructive CRC, without significant adverse effect on the survival of patients. Given the advantage of minimal invasion, SEMS may be a better alternative to DS for obstructive CRC. However, the conclusions remain to be discussed because of lacking high-quality randomized controlled trails.
自膨式金属支架(SEMS)作为一种“桥接手术”(BTS),已被用于数十年,以缓解结直肠癌(CRC)急性梗阻。然而,与造口术(DS)相比,SEMS 是否是一种安全的技术,可缓解梗阻而不影响患者的长期生存,目前仍未明确。本研究旨在阐明 SEMS 和 DS 的安全性和生存结局。
检索 Embase、PubMed 和 Medline 数据库,纳入截至 2020 年 10 月发表的研究,其中 SEMS 或 DS 作为 BTS 而不在同一阶段进行切除。最后一次检索时间为 2020 年 12 月 5 日。采用纽卡斯尔-渥太华量表(NOS)评估纳入研究的质量。主要并发症发生率、死亡率、3 年总生存率(OS)和永久性造口率作为结局。
本研究已在 INPLASY(注册号:2020100079)注册。纳入了 7 项符合条件的研究,涉及分别接受 SEMS 和 DS 治疗的 646 例和 712 例患者。SEMS 组的 Clavien-Dindo I/II 级并发症发生率明显低于 DS 组(8.68% vs. 16.85%;RR,0.59;95%置信区间(CI)0.41-0.84;P=0.004)。两组的 Clavien-Dindo III/IV 级并发症发生率无统计学差异(7.69% vs. 8.79%;RR,0.82;95% CI 0.54-1.27;P=0.37)。两组短期死亡率(5.16% vs. 4.53%;RR,1.25;95% CI 0.75-2.08;P=0.39)、3 年 OS(71.91% vs. 76.60%;RR,0.93;95% CI 0.86-1.01;P=0.10)和永久性造口率(22.08% vs. 27.54%;RR,0.84;95% CI 0.67-1.06;P=0.14)均无统计学差异。
在一定程度上,SEMS 是一种安全的急性结直肠梗阻 BTS 技术,对患者的生存无显著不良影响。鉴于微创的优势,SEMS 可能是结直肠梗阻的更好选择。然而,由于缺乏高质量的随机对照试验,结论仍有待讨论。